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Abstract
Objective
To identify the genetic cause of disease in 2 previously unreported families with forms of distal
hereditary motor neuropathies (dHMNs).
Methods
The ﬁrst family comprises individuals aﬀected by dHMN type V, which lacks the cardinal
clinical feature of vocal cord paralysis characteristic of dHMN-VII observed in the second
family. Next-generation sequencing was performed on the proband of each family. Variants
were annotated and ﬁltered, initially focusing on genes associated with neuropathy. Candidate
variants were further investigated and conﬁrmed by dideoxy sequence analysis and cose-
gregation studies. Thorough patient phenotyping was completed, comprising clinical history,
examination, and neurologic investigation.
Results
dHMNs are a heterogeneous group of peripheral motor neuron disorders characterized by
length-dependent neuropathy and progressive distal limb muscle weakness and wasting. We
previously reported a dominant-negative frameshift mutation located in the concluding exon of
the SLC5A7 gene encoding the choline transporter (CHT), leading to protein truncation, as
the likely cause of dominantly-inherited dHMN-VII in an extended UK family. In this study,
our genetic studies identiﬁed distinct heterozygous frameshift mutations located in the last
coding exon of SLC5A7, predicted to result in the truncation of the CHT C-terminus, as the
likely cause of the condition in each family.
Conclusions
This study corroborates C-terminal CHT truncation as a cause of autosomal dominant dHMN,
conﬁrming upper limb predominating over lower limb involvement, and broadening the clinical
spectrum arising from CHT malfunction.
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Distal hereditary motor neuropathies (dHMNs) are
a clinically and genetically heterogeneous group of diseases
characterized by distal lower motor neuron dysfunction
without major upper motor neuron or sensory in-
volvement. In 1993, Harding classiﬁed dHMN into 7
subtypes (dHMN-I to VII) according to the mode of in-
heritance and clinical features, since which classiﬁcation
has evolved further through improved knowledge of mo-
lecular pathogenesis. Previously, we identiﬁed a frameshift
(c.1497delG) mutation in SLC5A7 (NM_021815.2),
encoding the hemicholinium-3 (HC-3)-sensitive Na+/Cl-
dependent, presynaptic choline transporter (CHT;
NP_068587.1) critical for normal neuromuscular junction
(NMJ) signaling, as the cause of a dominantly-inherited
motor neuron disease (dHMN-VII).1 This variant resulted
in a translational frameshift of CHT, causing premature
termination (p.Lys499Asnfs*13) and protein truncation,
with near-complete deletion of the cytoplasmic
C-terminus. Transporter assays revealed signiﬁcant
reductions in HC-3-sensitive choline uptake due to the
p.Lys499Asnfs*13 mutation, consistent with a dominant-
negative mode of action.1 Here, we report additional
dominant truncating CHT mutations in 2 unrelated fami-
lies for which individuals were referred initially with di-
agnoses of amyotrophic lateral sclerosis (ALS) based on
a progressive pure motor neurogenic disorder with
hyperreﬂexia, and Charcot-Marie-Tooth (CMT) type II
based on distinct and progressive atrophy of the hand
muscles and gait diﬃculties. This clinical presentation is
then compared with the recently described phenotype
arising from recessively acting CHT mutations, consisting
of a spectrum of congenital myasthenic syndrome (CMS)
disorders, associated with biallelic SLC5A7 mutations.
Methods
Clinical studies
Detailed pedigree information was collated, and thorough
neurologic examination was performed in the proband,
mother, and 3 maternal uncles/aunts of family A, and the
proband, mother, and sister of family B. Nerve conduction
studies and/or needle EMG was performed in 4 individuals in
family A and the proband and sister of family B.
Genetic studies
DNA was extracted from peripheral blood samples obtained
from family members with informed consent. DNA for next-
generation sequencing performed on the proband of each
family was enriched for target regions using the Illumina
TruSight One-Sequence capture panel (family A) or the
Nextera Rapid Capture Expanded Exome kit (62 Mb) (family
B), with the prepared library sequenced on an Illumina HiSeq
2500 and annotation and variant ﬁltering using the Clinical
Sequence Analyzer and Miner (WuXi NextCODE). Cose-
gregation of each variant was conﬁrmed using dideoxy se-
quence analysis.
Information on these exomes, including a list of genes covered,
can be accessed at support.illumina.com/downloads/trusight_
one_sequencing_panel_product_ﬁle.html, and illumina.com/
documents/products/datasheets/datasheet_nextera_rapid_
capture_exome.pdf, respectively.
Standard protocol approvals, registrations,
and patient consents
Approval was obtained from the Institutional Review Board of
the University of Minnesota and the Ethical Standards
Committee of Antwerp Hospital Centre for clinical research
activities performed in this investigation. Written informed
consent was obtained from all research participants.
Results
Clinical findings
Family A, individual 1: (A:IV:1)
A 27-year-old woman was referred with a diagnosis of
possible ALS after a 1- to 2-year history of progressive
weakness in the hands without sensory symptoms, dysar-
thria, or dysphagia. Family history at the time was reported
to be negative for neurologic disease. There were no cog-
nitive deﬁcits, and cranial nerve examination, including
bulbar examination and articulation, was normal. Percep-
tion of touch, vibration, and pinprick were unremarkable.
Motor examination demonstrated marked atrophy in in-
trinsic hand muscles bilaterally, normal muscle tone, and
no fasciculations. Manual muscle testing demonstrated full
strength except in distal muscles (table 1). Reﬂexes were
brisk throughout, with vertical spread in the upper limbs
but without clonus or Babinski signs. Nerve conduction
studies demonstrated markedly attenuated median and
peroneal compound muscle action potentials (CMAPs)
with normal conduction velocities and no focal motor
conduction block, normal ulnar and tibial motor conduc-
tion studies, and normal sensory nerve action potential
amplitudes (table 2). Needle EMG demonstrated ﬁbrilla-
tion potentials, reduced interference patterns, and high-
amplitude long-duration motor unit potentials in distal
muscles of upper and lower limbs. A serum study of
Glossary
AChR = ACh receptor; ALS = amyotrophic lateral sclerosis; CHT = choline transporter; CMAP = compound muscle action
potential; CMS = congenital myasthenic syndrome; CMT = Charcot-Marie-Tooth; dHMN = distal hereditary motor
neuropathy; NMJ = neuromuscular junction.
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ganglioside GM-1 antibodies was negative. Hexosamini-
dase levels, SOD1 sequencing, CSF cell count, and protein
and glucose levels were normal (ﬁgure 1A).
Family A, individual 2: (A:III:2)
Twelve years later, the proband’s mother presented at age 60
years with a 3-year history of gradually progressive weakness
of ankle plantarﬂexion bilaterally. There was no history of
sensory symptoms, weakness in the upper limbs or proximal
lower limbs, dysphagia, or dysarthria. There were no cog-
nitive deﬁcits, and cranial nerve examination, including
bulbar examination and articulation, was normal. Sensory
examination demonstrated normal perception of touch and
vibration and an equivocal reduction in pinprick perception
in the toes. Motor examination demonstrated mild atrophy
of intrinsic muscles of the hands and feet. Muscle tone was
normal. No fasciculations were noted. Manual muscle test-
ing demonstrated full strength except for distal muscles
(table 1). Reﬂexes were brisk with vertical spread in the
upper limbs and normal in the lower limbs without clonus or
Babinski signs. Nerve conduction studies demonstrated at-
tenuated median, peroneal, and tibial CMAPs with normal
conduction velocities and no focal motor conduction
block, normal ulnar motor conduction studies, and normal
or borderline ﬁndings on orthodromic sensory nerve
conduction studies (table 2). Needle EMG demonstrated
ﬁbrillation potentials, reduced interference patterns, and
high-amplitude long-duration motor unit potentials in
distal muscles. Serum studies for ganglioside GM-1 and
Lyme antibodies were negative. Vitamin B12, copper lev-
els, CSF cell count, and protein and glucose levels were
normal. Laryngoscopy demonstrated normal vocal cord
function (ﬁgure 1A).
These patients have been followed for 14 and 2 years, re-
spectively, with no clinically signiﬁcant change in examination
or function, except for the development of median entrap-
ment at the wrist, conﬁrmed with electrodiagnostic study, in
the proband.
The mother of the proband has 4 living siblings, 3 of whom
have provided written consent to examination and genetic
evaluation, and 2 of these to electrodiagnostic testing, under
a protocol approved by the University of Minnesota In-
stitutional Review Board. None of these 3 had clinical or
electrodiagnostic evidence of motor neuropathy, and they
were wild type and had not inherited have the SLC5A7 variant
identiﬁed in the proband and her mother. The patients also
reported that their deceased maternal grandmother/mother
had hand deformities late in life that were believed to be due
to arthritis (A:II:3). No other family members are known to
have symptoms or signs of neuromuscular disease (ﬁgure 1A).
Table 1 Manual muscle testing studies on the MRC scale in patients with SLC5A7 mutations
Patient
Age at
examination, y
Finger extensor FDI Thumb adduction Ankle dorsiflexors Plantar flexors
R L R L R L R L R L
A:III:2 60 5 4+ 4 4+ 3 4+ 4 4 — —
A:IV:1 27 5 4+ 4 4 2 3 4 4+ 5 5
B:II:3 61 — — — — — — 4 4 4 4
B:III:1 42 4 4+ 2 2 0–1 0–1 0–1 0–1 4+ 4+
MRCscalemuscle testing: (5) normalpower; (4+) submaximalmovementagainst resistance; (4)moderatemovementagainst resistance; (3)movementagainst gravity
but not against resistance; (2) movement with gravity eliminated; (1) flicker of movement; (0) no movement; (—) not measured. MRC = Medical Research Council.
Table 2 Nerve conduction velocity studies in patients with SLC5A7 mutations
Patient
Age at
examination, y
R/
L
Median
motor
Ulnar
motor
Peroneal
motor Tibialmotor
Median
sensory
Ulnar
sensory
Sural
sensory
Amp CV Amp CV Amp CV Amp CV Amp CV Amp CV Amp CV
A:III:2 60 R 2.8 48.4 7.6 55.8 NR — 0.1 — 9.3 49.8 9.5 52.2 5.9 31.6
L 6.2 48.5 8.9 56.7 — — — — 9.1 54.9 8.8 46.2 — —
A:IV:1 27 R 0.5 47.6 8.55 57.4 0.3 33.0 5.1 48.2 39.4 58.3 17.4 64.4 41.3 55.0
B:III:1 42 R 0.1 39.0 1.3 55.1 0.4 41.9 0.2 43.6 18.1 47.2 7.2 46.7 23.3 58.3
L — — — — 0.9 39.6 — — — — — 25.2 58.7
Abbreviations:— = not measured; Amp = amplitude of distal response (motor, mV; sensory, μV); CV = conduction velocity of distal segment (in m/s); NR = no
response.
Abnormal values are indicated in bold.
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Family B, individual 1: (B:III:1)
A 41-year-old woman was ﬁrst seen by a neurologist at the age
of 24 years with a diagnosis of possible CMT type II. Prior
history reveals subtle diﬃculties with ﬁne motor skills in the
hands in primary school, at that time without gait diﬃculties.
Progressive diﬃculty running combined with frequent ankle
sprains became apparent at the age of 15 years. Distal weak-
ness in both upper and lower limbs progressed, and she used
ankle-foot orthoses from the age of 30 years. Gait autonomy is
currently well preserved with walking aids. Despite relatively
pronounced atrophy of the intrinsic hand muscles, she was
a nurse until the age of 39 years and is currently a head nurse
with more administrative tasks. The patient denies sensory
symptoms but recognizes a slight hoarseness that is more
pronounced with fatigue or upper respiratory tract infection
(ﬁgure 1B).
On examination, the patient had no cognitive deﬁcits. Cranial
nerve examination was normal aside from hoarseness (dys-
phonia), without dysarthria. Touch, pinprick, and vibration
sense and proprioception were normal. Motor examination
demonstrated bilateral pes cavus, hammer toes, and marked
distal atrophy in the lower limbs, most notable in the anterior
compartment. In addition, there was pronounced atrophy of
the intrinsic hand muscles (ﬁgure 1C). Manual muscle testing
demonstrated full strength in all proximal muscles and ab-
normal distal strength in the upper limbs (table 1). Reﬂexes
were markedly brisk, with exception of the Achilles tendon
reﬂex, which was absent. Hoﬀmann sign was present on the
right and absent on the left. Plantar reﬂexes were mute in
severely paretic feet. The patient had a steppage gait. Nerve
conduction studies demonstrated a pure motor axonal neu-
ropathy without conduction blocks (table 2). Routine con-
centric needle EMG showed chronic neurogenic changes, and
single-ﬁber EMG revealed mild to moderate abnormalities of
neuromuscular transmission in both orbicularis oculi and
extensor digitorum communis muscles. Formal speech anal-
ysis and laryngostroboscopy conﬁrmed the presence of a left
paramedian vocal fold paralysis.
Family B, individual 2 (B:III:2)
The older sister of the proband presented with a history of
progressive atrophy in the hand muscles and bilateral pes
cavus starting in her early twenties. At age 46 years, she had
distinct atrophy of the abductor pollicis brevis muscles and, to
a lesser extent, atrophy of the intrinsic hand and foot muscles.
Figure 1 Family pedigrees, clinical photographs, and multispecies alignment showing the effect of the 3 reported
mutations
(A–B) Pedigrees of families A and B showing affected (black), unaffected (white), and possibly affected (grey) individuals. Those clinically investigated are
indicated by * and thosewho had genetic testing are indicated by the test result, where (+/−) represents individuals heterozygous for the SLC5A7mutation and
(−/−) represents individuals homozygous for wild type. (C) Hands of individual B:III:1 showing pronounced atrophy of the intrinsic hand muscles. (D) Species
amino acid sequence alignment of the CHTC-terminal region, depicting the outcomes of the K499Nfs13, H521Qfs2, and K510Nfs2 alterations (arrows indicate
the position of polypeptide truncation, and additional aberrant amino acids are highlighted in yellow). The primary endocyticmotif (SEENMDKTILV-1°Motif) is
highlighted in blue (Ser522 to Val532), and the secondary endocytic motif (DELAL-2° Motif) is highlighted in green (Asp540 and Leu544).
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Like her sister, there was no sensory involvement. There was
no distinct gait diﬃculty aside from slight eversion of the feet.
Manual muscle testing demonstrated full strength in the
proximal muscles and minimally reduced strength in foot
dorsiﬂexion, without a manifest foot drop. Reﬂexes in the
upper limbs were normal; patellar and ankle reﬂexes were
bilaterally reduced; and plantar responses were ﬂexor. Nerve
conduction studies and needle EMG were consistent with
a pure motor axonal polyneuropathy (ﬁgure 1B).
Family B, individual 3 (B:II:3)
The mother of the proband, 61 years of age at examination,
demonstrated atrophy of intrinsic handmuscles, most notably
in the abductor pollicis brevis. This patient also presented
with atrophy of the foot muscles and the distal third of the
legs, as well as bilateral pes cavus. Manual muscle testing
demonstrated full strength in the proximal muscles and de-
creased strength in distal lower extremity muscles (table 1).
The patellar reﬂexes were reduced and ankle reﬂexes absent.
Other reﬂexes were normal including plantar responses. No
nerve conduction studies or needle EMGwas performed. The
clinical examination, however, is compatible with a distal
motor neuropathy with pronounced involvement of the hands
and is similar to the phenotype seen in her daughters, albeit
milder (ﬁgure 1B).
The mother of the proband has 6 siblings, one of whom was
reported to have gait diﬃculty. While no further information is
available on this individual (1B:II:2), this may indicate the
presence of other aﬀected family members. The 5 remaining
siblings and maternal grandparents are reportedly unaﬀected.
The proband has 2 unaﬀected siblings, and the children of both
aﬀected sister and unaﬀected brother show no symptoms.
Genetic findings
Initial analysis of variants in genes with known associations with
neuropathy identiﬁed a potentially deleterious heterozygous
sequence variant in SLC5A7 in each family: a heterozygous 2-bp
deletion in family A (NM_021815.2: c.1561_1562delCA) and
a 1-bp deletion in family B (NM_021815.2: c.1528delA). The
variant was conﬁrmed by dideoxy sequence analysis and found to
cosegregate appropriately for an autosomal dominant disorder in
each family.
Wild-type CHT comprises 580 amino acids predicted to en-
compass 13 transmembrane domains, with an extracellular
NH2-terminus and an intracellular COOH-terminus.
2,3 The
deletion in family A is predicted to result in a substitution of
glutamine for histidine at residue 521, followed by a pre-
mature stop codon, resulting in a truncation of the COOH
terminus (p.His521Glnfs*2). The variant in family B is pre-
dicted to result in a translational frameshift, substituting lysine
at amino acid position 510 for asparagine, and going on to
encode 1 additional aberrant amino acid before a premature
termination in translation (p.Lys510Asnfs*2). Similar to the
SLC5A7 c.1497delG/p.Lys499Asnfs*13 variant previously found
to be responsible for dHMN-VII,1 the c.1561-1562delCA and
c.1528delA variants identiﬁed here are predicted to result
in premature truncation of the protein. The family A
(c.1561_1562delCA) variant results in CHT truncation
by 59 amino acids with the inclusion of 1 aberrant glutamine
residue; p.His521Glnfs*2, whereas the family B variant
(c.1528delA) results in the same premature stop codon as the
previously described dHMN-VII (c.1497delG) variant,
resulting in truncation of the last 82 amino acids (p.-
Lys510Asnfs*2). A schematic to aid visualization of the pre-
dicted outcome of each variant on the polypeptide sequence
of CHT is shown in ﬁgure 2, A-D.
Online mutation analysis tools including PROVEAN (provean.
jcvi.org/index.php) and MutationTaster (www.mutationtaster.
org/) predicted both previously identiﬁed c.1497delG1 and
newly identiﬁed c.1561-1562delCA and c.1528delA variants to
have a deleterious eﬀect on CHT function (PROVEAN:
−55.034, −14.155, and −55.034; MutationTaster: 1, 0.99 and 1,
respectively). Conservation analysis indicates that the
C-terminal region aﬀected corresponds to a region of the
molecule that is highly conserved across many species
(ﬁgure 1D). TMHMM analysis (www.cbs.dtu.dk/services/
TMHMM/) for the in silico deﬁnition of transmembrane
domain architecture predicts that all 3 variants (ﬁgure 2, A-D)
will profoundly aﬀect polypeptide topology at the 39 CHT
terminus (data not shown).
Notably, all variants including the previously identiﬁed
c.1497delG (p.Lys499Asnfs*13) frameshift mutation responsible
for dHMN-VII1 and the newly identiﬁed c.1561-1562delCA
(p.His521Glnfs*2) and c.1528delA (p.Lys510Asnfs*2) muta-
tions are located in the last exon of the gene and will likely escape
nonsense-mediated mRNA decay leading to the generation of
a truncated polypeptide product. Consistent with each being
pathogenic, all 3 frameshift variants are absent from the gnomAD
database of ;138,000 controls (gnomad.broadinstitute.org/).
Discussion
We describe 2 families with novel C-terminal SLC5A7
mutations predicted to result in production of a truncated
CHT protein: family A (proband and mother) with a dHMN
phenotype associated with a cosegregating p.His521Gln*fs2
mutation and family B (proband, mother, and sister) also with
a dHMN phenotype associated with a cosegregating p.
Lys510Asnfs*2 mutation. These ﬁndings are in line with the
p.Lys499Asnfs*13 truncating CHT mutation that we pre-
viously reported in a large family with multiple individuals
aﬀected by dHMN-VII. In this original family, transporter
assays showed a signiﬁcant reduction in mutant transporter
activity compared with wild type (WT) likely due to
a dominant-negative mutational mechanism.1
Several clinical ﬁndings are of note in the families reported here.
First, the absence of vocal cord paralysis in family A represents
a notable clinical diﬀerence when compared with the proband
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of family B and the previously described family. Second, we ﬁnd
it notable that both patients in family A report a relatively
abrupt progression of symptoms over a few years, followed by
clinical stability. Progression is more gradual in family B.
Electrodiagnostic ﬁndings indicate that denervation, which is
accentuated distally in both patients, is chronic and likely
preceded initial symptoms. On presentation, the ﬁndings of
family A’s proband raised concern about possible ALS because
of deﬁnite lower motor neurone signs in association with
hyperreﬂexia and reﬂex spread, which also holds true for family
B’s proband. Thus, several features were atypical or cautionary
for a diagnosis of sporadic ALS, including the relatively early
age at onset, arguably slow progression, and the absence of
spasticity, clonus, or extensor plantar responses, features that
would represent unequivocal evidence of upper motor neurone
dysfunction. Given this, the fact that hyperreﬂexia was not seen
in all patients, and the lack of a compelling mechanism for
upper motor neurone involvement, the signiﬁcance of the
hyperreﬂexia seen in some patients is unknown. Thus, our
patients demonstrate that a diagnosis of ALS should be made
with caution in individuals presenting with distal weakness and
atrophy and hyperreﬂexia withoutmore compelling evidence of
upper motor neurone disease.
This phenotypic variability is again mirrored in the absence of
hoarseness in both mother and sister in family B, who also
show a milder overall phenotype and later age at onset. In
both families, several aﬀected individuals display pronounced
and early involvement of hand intrinsic muscles. This could be
a useful clinical clue to help orient diagnosis toward SLC5A7.
Upper limb predominance is also a known feature of dHMN
subtypes caused by BSCL2 and GARS mutations.4
The CHT cytoplasmic C-terminus that is truncated by the p.
His521Gln*fs2 and p.Lys510Asnfs*2 mutations reported here
and the p.Lys499Asnfs*13 reported previously,1 contain
sequences known to drive constitutive endocytosis. A primary
endocytic motif (SEENMDKTILV-1° Motif) between CHT
amino acids Ser522 to Val532 contains a dileucine-type motif
and supports dynamin-dependent endocytosis.5 A secondary
motif (DELAL-2° Motif) is also present between Asp540 and
Leu544 of the C-tail that supports enhanced surface expres-
sion of CHT but does not exhibit a dominant capacity for
surface traﬃcking.5 The CHT truncating mutations described
in all 3 families result in the complete elimination of
SEENMDKTILV-1° and DELAL-2° motifs (ﬁgure 1D), sug-
gesting that these mutations may lead to impaired choline
uptake via the loss of dynamin-dependent endocytosis. Of
interest, inspection of online genome sequence databases via
gnomAD (gnomad.broadinstitute.org/) identiﬁes 3 rare het-
erozygous CHT truncating variants (present in 11 individu-
als) in the last exon of SLC5A7. Notably, all 3 aﬀect residues
Figure 2 Schematic displaying the 3 described CHTmutant proteins alongsidewild typemolecule (Adapted from reference
2, using Microsoft Powerpoint Software)
Schematic indicating the transmembrane architecture and C-terminal truncation of both sequence variants identified in the current study alongside the
previously published dHMN-VII-associated CHT sequence variant (A: H521Qfs*2; B: K510Nfs*2; C: K499Nfs*13; D: wild type). Dark circles represent amino
acids that are conserved across human CHT, mouse Cht1, and the C. elgans CHT ortholog. Potential protein kinase A phosphorylation sites are indicated by
light circles containing a letter P, and potential protein kinase C phosphorylation sites are indicated by dark circles containing a letter P. Potential N-
glycosylation sites are indicated by gray “tree-like” structures.
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located after the primary endocytic motif between residues
Ser522 and Val532 (at Lys538, Arg548, and Thr558). This
may indicate that variants resulting in CHT truncation before
the endocytic motif may be the primary driver for dHMN-
related phenotypes. This may occur via 2 possible mecha-
nisms. First, the endocytotic sequences are used to bud
proteins for transport between the endoplasmic reticulum and
golgi apparatus, allowing them to enter traﬃcking pathways to
the nerve terminus. Failure or abnormalities in this process,
due to a lack of these motifs, may therefore result in cell soma
accumulation and reduction in synaptic membrane CHT and
choline uptake. Second, endocytotic sequences are likely to
have a central role in the binding of endocytic adaptors (e.g.,
AP2/AP3) in routing CHT to synaptic vesicles.6 The pres-
ence of CHT in the synaptic vesicles provides a rapid supply
of CHT at the presynaptic nerve terminus, which is essential
to ensure that the choline is eﬃciently recaptured from the
rapidly hydrolysed ACh in the synaptic cleft. Defects in this
mechanism would allow choline to diﬀuse away from the
synaptic cleft and may result in an overall reduction in choline
uptake. However, it remains unclear whether the 3 individuals
listed in online databases gnomAD and ExAC, with an ap-
parent heterozygous variant in the last exon of SLC5A7 that
would likely eliminate the primary endocytic motif (Tyr466
and Arg382), may display features of dHMNor whether CHT
truncation at these residues may be variably or nonpenetrant.
Before the discovery of impaired CHT activity, NMJ dys-
function had not previously been implicated in the dHMNs.
However, it is a well recognized cause of CMS, a genetically
heterogeneous group of neuromuscular disorders, which is
known to result from mutations in genes that encode pre-
synaptic and postsynaptic proteins at the NMJ such as choline
acetyltransferase (CHAT), ACh receptors, receptor-associated
protein of the synapse (RAPSN), and downstream of kinase 7
(DOK7).7–11 More recently, homozygous and compound
heterozygous mutations in SLC5A7 have been reported in
a spectrum of CMS disorders ranging from arthrogryposis to
neonatal presentation with hypotonia, fatigable muscle weak-
ness, and respiratory insuﬃciency with recurrent apneas. These
include missense mutations located upstream of the cytoplas-
mic tail and a singleN-terminal nonsensemutation (p.Ile42*)12
likely to result in nonsense mediated decay. The likely result of
these mutations is the production of exclusively mutant CHT
polypeptide(s) with intact C-terminal and endocytic
motifs.12,13 dHMN types V and VII do not share apparent
phenotypic features with CMS other than vocal cord in-
volvement. The cardinal feature of muscle fatigability is absent
in both aﬀected families as are ophthalmoparesis, ptosis, and
bulbar weakness; furthermore, unlike CMS, features do not
appear until adulthood. No signs of neuropathy have been
reported in autosomal recessive SLC5A7 CMS, although it is
possible that these features might develop with time. In patient
B:III.1, single-ﬁber EMG revealedmild tomoderately increased
jitter measurements in the absence of impulse blocking in both
Musculus orbicularis oculi and the Musculus extensor dig-
itorum communis. These ﬁndings are diﬃcult to interpret in
this clinical context because a neurogenic process such as
dHMN is known to cause secondary alterations in NMJ
function, although we would expect this phenomenon mainly
in a clinically aﬀected distal muscle and less so in the Musculus
orbicularis oculi. This single observation is insuﬃcient to
conﬁrm a primary defect of NMJ transmission in patients with
SLC5A7-linked dHMN.
The very diﬀerent phenotypes seen in dominant and recessive
SLC5A7-associated CHT disorders are likely to result from
speciﬁc and diﬀering outcomes particular to each class of
mutation on CHT activity and traﬃcking of the molecule.1,9
Although the C-terminal truncating (dominant-negative)
mutations greatly reduce CHT functionality, their deleteri-
ous impact on overall CHT activity appears to be less than in
the case of pathogenic missense (recessive) variants, which
have compounding deleterious outcomes on both CHT
traﬃcking and speciﬁc activity.12,13
Speciﬁc clinical outcomes may also reﬂect the speciﬁc func-
tional impact on the NMJs that vary across human muscle
ﬁber types, placing diﬀering demands on the CHT protein.
The common “en plaque” NMJ has a single innervation to
each muscle ﬁber, whereas “en grappe” NMJs have diﬀuse,
multiterminal connections. These “en grappe” NMJs in-
nervate tonic muscle ﬁbers, which can continuously release
ACh by almost an order of magnitude longer than twitch
terminals. They are present only in a small number of human
muscles, namely the extraocular, stapedius, tensor tympani,
laryngeal, and tongue.14 CHT, and its central role in choline
recycling, may be of particular importance in this sustained,
high-frequency ACh signaling and therefore may result in
fatigability in these muscle groups.
Here, we provide additional convincing genetic and functional
evidence to conﬁrm dominant mutations leading to impaired
CHT function as a cause of dHMN phenotypes and demon-
strate that an absence of vocal cord involvement in patients
with dHMNwith upper limb involvement predominating over
lower limb does not preclude SLC5A7 CHT involvement.
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